Lead Product(s): MIV-711
Therapeutic Area: Musculoskeletal
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2020
The study demonstrated significant effect on changes in bone and cartilage degradation after six months of treatment with MIV-711.